Remix Therapeutics Closes $60 Million Financing To Advance Rem-422, Pipeline Of Small Molecule Therapies Designed To Reprogram Rna Processing To Treat Disease
Remix Therapeutics Closes $60 Million Financing To Advance Rem-422, Pipeline Of Small Molecule Therapies Designed To Reprogram Rna Processing To Treat Disease
01/03/24, 12:07 PM
Location
watertownMoney raised
$60 million
Industry
biotechnology
Investors
Willett Advisors, Wtt Investment, Surveyor, Casdin Capital, Arch Venture Partners, Alexandria Venture Investments, Foresite Capital, Atlas Venture, The Column Group
Remix Therapeutics (Remix), a clinical-stage biotechnology company developing small molecule therapies to modulate RNA processing and address the underlying drivers of disease, today announced the close of a $60 million financing led by The Column Group. The financing includes participation from existing investors Atlas Venture, Foresite Capital, Alexandria Venture Investments, Arch Venture Partners, Casdin Capital, and Surveyor (a Citadel company) along with new investors WTT Investment, Willett Advisors, and others. The funds will support clinical development of the company's lead program, REM-422, and further advancement of a pipeline of RNA processing targeted therapeutics.
Company Info
Location
watertown, south dakota, united states
Additional Info
Remix launched in 2020 with a vision to transform patient's lives through modulation of RNA processing. Our breakthrough science provides a path to identify small molecules that impact the expression of disease driving mRNAs and proteins. We take on the challenge of addressing drug targets in diseases of high unmet medical need to bring new therapeutic options to patients. Remix has a commitment to demonstrate the highest levels of scientific integrity with urgency because those patients are counting on us to deliver. With an in-house technology platform built from scratch, we have rapidly generated multiple drug discovery programs that are advancing towards the clinic.